Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on invested capital (ROIC) is N/A as of the fiscal period ended Monday, March 31, 2025.
Trailing-twelve-month return on invested capital at each fiscal quarter end; no daily interpolation. Q3 FY2024 (2025-03-31): -119.47%.
RETURN ON INVESTED CAPITAL (ROIC)
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG TTM
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 3Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 5Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 10Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 15Y
N/A
RETURN ON INVESTED CAPITAL (ROIC) AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Lunai Bioworks Inc.
Market Cap
$5.17M
Return on Invested Capital (ROIC)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.20M
Return on Invested Capital (ROIC)
-225.12%
TTM Avg
-13.17%
3Y Avg
-9.09%
5Y Avg
-9.09%
Market Cap
$5.21M
Return on Invested Capital (ROIC)
-179.58%
TTM Avg
-259.96%
3Y Avg
-220.56%
5Y Avg
-170.22%
Market Cap
$5.32M
Return on Invested Capital (ROIC)
-156.69%
TTM Avg
-654.50%
3Y Avg
-599.09%
5Y Avg
-420.09%
Market Cap
$5.02M
Return on Invested Capital (ROIC)
-126.69%
TTM Avg
-289.57%
3Y Avg
-198.60%
5Y Avg
-147.26%
Market Cap
$5.01M
Return on Invested Capital (ROIC)
-35.07%
TTM Avg
-9.54%
3Y Avg
2.54%
5Y Avg
2.54%
Market Cap
$4.96M
Return on Invested Capital (ROIC)
-27.41%
TTM Avg
-21.46%
3Y Avg
-17.98%
5Y Avg
-12.44%
Market Cap
$4.83M
Return on Invested Capital (ROIC)
-38.23%
TTM Avg
-122.97%
3Y Avg
-1403.32%
5Y Avg
-860.06%
Market Cap
$5.54M
Return on Invested Capital (ROIC)
-94.08%
TTM Avg
-1223.16%
3Y Avg
-731.00%
5Y Avg
-532.24%
| NAME | MARKET CAP | RETURN ON INVESTED CAPITAL (ROIC) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lunai Bioworks Inc. (LNAI) | $5.17M | N/A | N/A | N/A | N/A |
| Liminatus Pharma, Inc. Class A Common Stock (LIMN)vs › | $5.20M | -225.12% | -13.17% | -9.09% | -9.09% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.21M | -179.58% | -259.96% | -220.56% | -170.22% |
| Alzamend Neuro Inc (ALZN)vs › | $5.32M | -156.69% | -654.50% | -599.09% | -420.09% |
| Imunon, Inc. (IMNN)vs › | $5.02M | -126.69% | -289.57% | -198.60% | -147.26% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $5.01M | -35.07% | -9.54% | 2.54% | 2.54% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.96M | -27.41% | -21.46% | -17.98% | -12.44% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.83M | -38.23% | -122.97% | -1403.32% | -860.06% |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.54M | -94.08% | -1223.16% | -731.00% | -532.24% |
| Lexaria Bioscience Corp. (LEXX)vs › | $4.79M | -175.26% | -258.55% | -208.94% | -173.09% |
ROIC
N/A
ROE
N/A
ROIC = NOPAT / Invested Capital, where NOPAT = Operating Income × (1 − effective tax rate) and Invested Capital = Total Assets − (Current Liabilities − Short-Term Debt)
Return on invested capital measures the after-tax operating return a company earns on the capital invested in the business. TGMCharts computes it from reported statements: trailing-twelve-month operating income after tax, over invested capital at the latest balance sheet — total assets less the non-interest-bearing current liabilities (payables, accruals, deferred revenue) that fund them; short-term debt stays in the capital base. The tax rate is the period's own effective rate (income tax ÷ pretax income), capped at 45%; when pretax income is zero or negative, or the tax line is a net benefit, no tax is deducted — the operating figure is shown untaxed rather than adjusted by an assumed rate. Not shown for banks, insurers or funds.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON INVESTED CAPITAL (ROIC) |
|---|---|
| 2025-03-31 | -119.47% |
| 2024-12-31 | -134.24% |
| 2024-09-30 | -116.04% |
